| Identification | Back Directory | [Name]
HUHS015 | [CAS]
1453097-13-6 | [Synonyms]
HUHS015
HUHS-015;HUHS 015
4-Benzyl-3-methyl-1-(6-methyl-1H-benzo[d]imidazol-2-yl)-1H-pyrazol-5-ol
1H-Pyrazol-5-ol, 3-methyl-1-(6-methyl-1H-benzimidazol-2-yl)-4-(phenylmethyl)- | [Molecular Formula]
C19H18N4O | [MDL Number]
MFCD28502088 | [MOL File]
1453097-13-6.mol | [Molecular Weight]
318.37 |
| Chemical Properties | Back Directory | [Boiling point ]
585.2±42.0 °C(Predicted) | [density ]
1.30±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:34.0(Max Conc. mg/mL);106.79(Max Conc. mM) | [form ]
A crystalline solid | [pka]
8.12±0.50(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
HUHS 015 is used in preparation of arylpyrazolol derivatives as antigen-1 (PCA-1/ALKBH3) inhibitors for anti-prostate cancer drugs. | [in vivo]
HUHS015 potently suppresses the growth of DU145 cells in a mouse xenograft model[1].
HUHS015 displays 7.2% bioavailability (BA) in rats after oral administration[1].
| Animal Model: | Nude mice[1] | | Dosage: | 32 mg/kg | | Administration: | Subcutaneous injection; daily; 6 days | | Result: | Has inhibitory effect on the growth of subcutaneously implanted DU145, without limiting weight gains after a 6 days continuous administration. |
|
|
|